Aquest lloc web fa servir cookies pròpies i de tercers per millorar l’experiència de navegació, i oferir continguts i serveis d’interès. En continuar la navegació entenem que acceptes la nostra política de cookies. Per a més informació consulta aquí.
The demand for hospital acquired disease testing market is rising at double-digit rates right now. There has been a huge rise in the number of health care facilities around the world, fueled by the increasing population and modernization of healthcare infrastructure. As a result, the number of HAIs is on the rise, pushing up the market for hospital acquired disease tests. Furthermore, microarrays, polymerase chain reaction (PCR), real-time position systems (RTLSs), and solid-phase hybridization are now available on the market as a result of advanced technologies and scientific advances for preventing, diagnosing, and controlling HAIs. HAIs can be effectively avoided in both patients and staff using strategies like RTLS. Other factors driving the market’s growth include increasing patient perception of HAIs and governments enacting legislation that penalises hospitals with a high incidence of HAIs. North America, led by Europe, is projected to lead the global market in terms of sales over the forecast period, owing to favourable government measures to combat nosocomial infections and reimbursement programmes, which are expected to propel the target market forward.